“Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S16, https://doi.org/10.25251/skin.2.supp.16.